Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeLuRide-006 first-line EIK1001 plus pembrolizumab in advanced melanoma
MOH_2025-03-26_013989Phase 3Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BDB001 and pembrolizumab in melanoma (5 arms), sponsored by Eikon Therapeutics. Primary endpoints: Optimal dose of EIK1001 in combination with pembrolizumab, Progression-free survival and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
BDB001pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2025-03-26_013989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-26_013989.